2014年ESC肥厚型心肌病心脏性猝死指南有效性的系统评价与荟萃分析
本研究通过系统评价与荟萃分析评估2014年ESC指南推荐的HCM Risk-SCD模型对肥厚型心肌病患者5年内SCD风险的预测性能。纳入6项研究共7291例患者,低、中、高危患者SCD实际发生率分别为1.01%、2.43%和8.4%,表明该模型风险分层准确,可用于指导ICD治疗。
要点
- HCM Risk-SCD模型将患者分为低危(<4%)、中危(4%-<6%)和高危(≥6%),5年SCD实际发生率与预测风险相符。
- 68%的SCD终点事件发生在预计5年风险≥4%的患者中,该群体占总队列的30%。
- 该模型可按照2014年ESC指南指导ICD一级预防决策。
核心结论
- HCM Risk-SCD模型提供的风险估计准确,可按照2014年ESC指南用于指导ICD治疗。
研究设计与样本
- 系统评价与荟萃分析,方案注册于PROSPERO(CRD42017064203)。
- 纳入无心脏骤停史的未选择成年肥厚型心肌病患者纵向观察队列,并预先纳入HCM Risk-SCD原始开发研究。
- 最终纳入6项独立研究,共7291例患者。
主要发现
- 7291例患者中,70%为低危、15%为中危、15%为高危。
- 5年内共发生184例(2.5%)SCD终点事件。
- 68%的SCD终点事件发生在预计5年风险≥4%的患者中,该群体占总队列的30%。
- 随机效应模型汇总的SCD终点发生率:低危患者1.01%(95%CI 0.52-1.61),中危患者2.43%(95%CI 1.23-3.92),高危患者8.4%(95%CI 6.68-10.25)。
关键数值与推荐
- 2014年ESC指南定义低危为预测风险<4%,中危为4%-<6%,高危为≥6%。
临床怎么用
- 临床可采用HCM Risk-SCD模型评估肥厚型心肌病患者5年SCD风险,并据此按照2014年ESC指南选择ICD一级预防。
局限性
- 仅6项(0.9%)独立研究符合纳入标准,纳入研究数量较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In 2014, the European Society of Cardiology (ESC) recommended the use of a novel risk prediction model (HCM Risk-SCD) to guide use of implantable cardioverter defibrillators (ICD) for the primary prevention of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). We sought to determine the performance of HCM Risk-SCD by conducting a systematic review and meta-analysis of articles reporting on the prevalence of SCD within 5 years of evaluation in low, intermediate and high-risk patients as defined by the 2014 guidelines (predicted risk <4%, 4%-<6% and ≥6%, respectively). METHODS: The protocol was registered with PROSPERO (registration number: CRD42017064203). MEDLINE and manual searches for papers published from October 2014 to December 2017 were performed. Longitudinal, observational cohorts of unselected adult patients, without history of cardiac arrest were considered. The original HCM Risk-SCD development study was included a priori. Data were pooled using a random effects model. RESULTS: Six (0.9%) out of 653 independent publications identified by the initial search were included. The calculated 5-year risk of SCD was reported in 7291 individuals (70% low, 15% intermediate; 15% high risk) with 184 (2.5%) SCD endpoints within 5 years of baseline evaluation. Most SCD endpoints (68%) occurred in patients with an estimated 5-year risk of ≥4% who formed 30% of the total study cohort. Using the random effects method, the pooled prevalence of SCD endpoints was 1.01% (95% CI 0.52 to 1.61) in low-risk patients, 2.43% (95% CI 1.23 to 3.92) in intermediate and 8.4% (95% CI 6.68 to 10.25) in high-risk patients. CONCLUSIONS: This meta-analysis demonstrates that HCM Risk-SCD provides accurate risk estimations that can be used to guide ICD therapy in accordance with the 2014 ESC guidelines. REGISTRATION NUMBER: PROSPERO CRD42017064203;Pre-results.
引用
- O'Mahony C, Akhtar MM, Anastasiou Z, et al. Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart. 2018. PMID: 30366935. doi:10.1136/heartjnl-2018-313700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。